Clinical trials: T1DM
T1DM, Sleep Disorders, Circadian Rhythm
Influence of Circadian Clock on Hormonal, Metabolic, Neurocognitive Markers in Adolescents With and Without Diabetes
Type 1 diabetes mellitus (T1DM), makes its appearance during childhood and youth, but management implications last till late adulthood.
- Conditions
- T1DM, Sleep Disorders, Circadian Rhythm, ADHD, Memory Impairment
- Trial name
- NCT04054934
- Testing
- Reversed Circadian Rhythm, Normal Circadian Rhythm
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assaf-Harofeh Medical Center
Type 1 Diabetes, Vitamin D Deficiency/Insufficiency
The Effects of Vitamin D on Glycemic Control and Proinflammatory Markers in Adolescents With T1DM
The investigators are conducting a prospective cross-over study to evaluate the effects of vitamin D supplementation on diabetes control and the pro-inflammatory markers involved in microvascular complications in adolescents with…
- Trial name
- NCT01697228
- Testing
- Vitamin D
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Children's Hospital Los Angeles
Type1 Diabetes Mellitus
BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus
BOL-DP-o-05 as an Add-On Treatment for Preservation of Beta-Cell Function in Subjects With Newly-Diagnosed Type 1 Diabetes Mellitus (T1DM)
- Trial name
- NCT04102202
- Testing
- BOL-DP-o-05
- Sponsor
- Breath of Life International Pharma Ltd
Type 1 Diabetes Mellitus, T1DM
Type 1 Diabetes Extension Study
This is a multi-center, prospective, non-interventional study that focuses on the long- term effects following participation in selected ITN new-onset Type1 Diabetes Mellitus studies with immunomodulatory agents (T1DM, T1D).
- Conditions
- Type 1 Diabetes Mellitus, T1DM, T1D
- Trial name
- T1DES (NCT02734277)
- Where
- 12 sites in United States
- Volunteers
- 111 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Type 1 Diabetes Mellitus (T1DM), Healthy Control
Environmental Determinants of Type 1 Diabetes Risk
To analyze the environmental risk factors for type 1 diabetes in China.
- Conditions
- Type 1 Diabetes Mellitus (T1DM), Healthy Control, Relatives to/Carers of Patients
- Trial name
- NCT07835724
- Where
- China
- Volunteers
- 11,240 people, healthy volunteers welcome
- Sponsor
- Second Xiangya Hospital of Central South University
Kidney Transplant, Familial Hypercholesterolaemia
Cardiovascular Risk in Children With Chronic Conditions Study
Children living with chronic health conditions face a higher risk of developing cardiovascular diseases than their peers, largely due to the accelerated aging of the heart and blood vessels.
- Conditions
- Kidney Transplant, Familial Hypercholesterolaemia, Type 1 Diabetes Mellitus (T1DM), Type 2 Diabetes Mellitus (T2DM)
- Trial name
- CR3C (NCT07086989)
- Where
- 3 sites in Hungary
- Volunteers
- 300 people
- Sponsor
- Semmelweis University
Type 1 Diabetes
Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)
The goal of this application is to evaluate the safety and efficacy of atorvastatin as a potential treatment to preserve beta cell function in children and young adults with newly diagnosed type 1 diabetes (T1DM).
- Trial name
- TIDM (NCT00529191)
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Philadelphia
Type 1 Diabetes
Characterization of Autoreactive Regulatory and Conventional CD4 T Cells in Recent Onset Type 1 Diabetes and Control Individuals
Type 1 diabetes (T1D) is caused by an autoimmune response leading to the destruction of pancreatic beta cells. The disease association with particular HLA class II alleles, particularly HLA-DQ8, indicates the implication of CD4 T…
- Trial name
- CARegT1D (NCT06427421)
- Testing
- Frequency of Treg and Teffs, Phenotype of Treg and Teffs, RNA seq analysis
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Type 1 Diabetes Mellitus
Study of Safety and Efficacy of CFZ533 in Type 1 Diabetes Pediatric and Young Adult Subjects
The study was a Phase 2, multicounty, multicenter, non-confirmatory, investigator- and subject masked, randomized, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of CFZ533 on…
- Trial name
- CCFZ533X2207 (NCT04129528)
- Testing
- CFZ533
- Where
- 12 sites in Belgium, Germany and 4 more
- Volunteers
- 44 people
- Sponsor
- Novartis Pharmaceuticals
Type 1 Diabetes, Treatment
Influence of Type 1 Diabetes (T1DM) Treatment Type on Mental Workload
Influence of the type of treatment for type 1 diabetes (pump versus multiple injections versus closed loop) on the treatment burden of children and adolescents and their parents.
- Trial name
- CHAM&DIAB (NCT06165159)
- Testing
- children and adolescents with type 1 diabetes and their parents
- Where
- France
- Volunteers
- 800 people
- Sponsor
- University Hospital, Angers
T1DM
Glycemic Control and Treatment Satisfaction in Children With Type 1 Diabetes Using Insulin Pumps
Background: The use of insulin pumps in pediatric patients with type 1 diabetes(T1D) has expanded, with lack of data comparing between the different devices.
- Trial name
- NCT03697369
- Volunteers
- 60 people
- Sponsor
- Assaf-Harofeh Medical Center
Type 1 Diabetes Mellitus
Pilot Study: Intensive Education in a Residential Camp Setting for Families of Young Children With Type 1 Diabetes
18 preschool aged children and their families will attend structured, multidisciplinary, family-centered intensive education sessions over a 3-day weekend in a residential camp setting to address the unique challenges of managing…
- Trial name
- TotCamp (NCT02432586)
- Testing
- Intensive Education
- Volunteers
- 18 people
- Sponsor
- University of Texas Southwestern Medical Center
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
The purpose of this study is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo infusion.
- Trial name
- DEFEND-1 (NCT00678886)
- Testing
- otelixizumab infusion plus physician determined standard of care
- Where
- 109 sites in United States, Canada and 7 more
- Volunteers
- 272 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes, Puberty: >Tanner 2 Breast Development or Testis >4ml
Rosiglitazone and Insulin in T1DM Adolescents
Type 1 Diabetes is the most common life-long disorder with onset in childhood. Patients need insulin injections, blood sugar monitoring several times each day, and adhere to a strict diet.
- Trial name
- NCT00372086
- Testing
- Rosiglitazone
- Where
- Australia
- Volunteers
- 32 people
- Sponsor
- The University of New South Wales
Treatment of Type I Diabetes Mellitus.
Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy
Phase IB will evaluate the safety of autologous, ex vivo-engineered, co-stimulation impaired dendtritic cells to maintain and improve functional residual beta cell mass in new onset Type I Diabetes Mellitus (T1DM) patients.
- Trial name
- NCT01947569
- Testing
- Biological
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- DiaVacs, Inc.
Type 1 Diabetes Mellitus
Pilot Study of Hippocampal Function in Type 1 Diabetes Mellitus (T1DM)
This study is an expansion of a previous study done to determine how thinking skills relate to hypoglycemia (low blood sugar) and certain regions of the brain in children and adolescents.
- Trial name
- ASSET (NCT00918801)
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Type 1 Diabetes Mellitus, T1D
CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103.
- Conditions
- Type 1 Diabetes Mellitus, T1D, T1DM, T1DM - Type 1 Diabetes Mellitus
- Trial name
- NCT06783309
- Testing
- CNP-103
- Where
- 45 sites in United States
- Volunteers
- 72 people
- Sponsor
- COUR Pharmaceutical Development Company, Inc.
Diabetes Mellitus Type 1
Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis
Hypothesis: Basal insulin analogs with continuous 24-hour delivery of insulin improve glycemic control during the first year of treatment of children/adolescents with type 1 diabetes mellitus (T1DM)by preserving endogenous…
- Trial name
- BAS (NCT01271517)
- Testing
- NPH insulin, Glargine, Detemir
- Where
- Sweden
- Volunteers
- 120 people
- Sponsor
- Karolinska Institutet
Diabetes Mellitus, Type 1
Trial of Otelixizumab for Adolescents and Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-2
DEFEND-2 is a Phase 3 confirmatory study for the Phase 3 DEFEND-1 study. The study objective is to find out if an 8-day series of otelixizumab infusions leads to greater improvement in insulin secretion as compared with placebo.
- Trial name
- DEFEND-2 (NCT01123083)
- Testing
- Otelixizumab
- Where
- Italy
- Volunteers
- 179 people
- Sponsor
- GlaxoSmithKline
Type 1 Diabetes Mellitus
Protege Extension Trial - Long Term Follow Up Trial for Subjects Who Completed the Protege Study (CP-MGA031-01)
The purpose of this study is to assess the long term safety and efficacy in subjects with Type 1 Diabetes Mellitus who completed the Protege Study (CP-MGA031-01).
- Trial name
- NCT00870818
- Testing
- Blood samples for safety, Patient reported outcome questionnaires, Analysis of T-cell subsets
- Where
- United States
- Volunteers
- 219 people
- Sponsor
- MacroGenics